First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas
GWN323(抗GITR)单药治疗以及与spartalizumab(抗PD-1)联合治疗晚期实体瘤和淋巴瘤患者的首次人体I/Ib期开放标签剂量递增研究
期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2021-002863
Piha-Paul, Sarina A; Geva, Ravit; Tan, Tira J; Lim, Darren Wt; Hierro, Cinta; Doi, Toshikiko; Rahma, Osama; Lesokhin, Alexander; Luke, Jason John; Otero, Javier; Nardi, Lisa; Singh, Angad; Xyrafas, Alexandros; Chen, Xinhui; Mataraza, Jennifer; Bedard, Philippe L